BISHYDROXYCOUMARIN (DICUMAROL) THERAPY IN MYOCARDIAL INFARCTION

Publisher Website
Google Scholar
Abstract
FOLLOWING the animal experimentation by Solandt, Nassim, and Best * on the prevention of mural thrombi formation and extension of coronary thrombosis with the use of heparin and following the synthesis of bishydroxycoumarin (Dicumarol), many reports † appeared in the literature favoring the use of bishydroxycoumarin therapy in myocardial infarction. The routine use of bishydroxycoumarin in myocardial infarctions was advocated by Wright and associates ‡ in their report of the Committee for Evaluation of Anticoagulants in the Treatment of Coronary Thrombosis with Mycardial Infarction, under the auspices of the American Heart Association. More recently however, many reports have appeared § questioning the routine use of anticoagulants in the treatment of myocardial infarction. It was our purpose, in undertaking this study, to determine the results of anticoagulant therapy in myocardial infarction as it is carried out in a private hospital, in the daily practice of various physicians, as internists, cardiologists, and general

This publication has 0 references indexed in Scilit: